Conditions: Irritable Bowel Syndrome
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 71
Healthy volunteers: no

Brief summary:
A study of the efficacy and safety of Lubiprostone in subjects diagnosed with IBS-M/IBS-U.

Detailed description:
To assess the efficacy and safety of oral lubiprostone, as compared to matching placebo, when administered orally (at 8 mcg twice daily \[BID\]) in subjects diagnosed with IBS-M/IBS-U.

Arms:
arm 1: Participants receive 8 mcg lubiprostone capsules twice daily (BID) arm 2: Participants receive 0 mcg capsules BID

Interventions: intervention 1: Lubiprostone intervention 2: Placebo
Intervention descriptions: intervention 1: 8 mcg administered orally twice daily (BID) intervention 2: Matching placebo, 0 mcg administered orally twice daily (BID)

Protocol document: